Last update Oct. 30, 2023

Amprenavir

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Amprenavir is an antiretroviral, HIV protease inhibitor, with activity against HIV. It is used in the treatment of HIV infection and AIDS. It is used with other aniretrovirals because viral resistance emerges rapidly if it is used as a monodrug. Oral administration.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very high percentage of protein binding, moderately high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.

Ampreanvir has been withdrawn from the market in many countries.

"Individuals with HIV who are on antiretroviral treatment (ART) with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision". (Panel 2022 p ix)


See below the information of this related product:

Alternatives

  • Bictegravir ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Darunavir (DRV) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Emtricitabine (FTC) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Lamivudine (3TC) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nevirapine (NVP) (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Tenofovir (TAF / TDF) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Zidovudine (ZDV / AZT) ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Amprenavir in other languages or writings:

Group

Amprenavir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Amprenavir in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 506 daltons
Protein Binding 90 %
VD 6 l/Kg
pKa 13.6 -
Tmax 1 - 2 hours
7.1 - 10.6 hours

References

  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2023 Consulted on June 16, 2023 Abstract Full text (link to original source)
  2. EMEA Amprenavir Fiche técnica 2009 Full text (in our servers)
  3. EMEA Amprenavir Data Sheet 2009 Full text (in our servers)

Total visits

3,212

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM